Grazoprevir sodium salt
Based on 29 publication(s) in Google Scholar
Grazoprevir sodium salt (MK-5172 sodium salt) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with Kis of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively. Grazoprevir sodium salt inhibits SARS-CoV-2 3CLpro activity.
For research use only. We do not sell to patients.
- CAS No.: 1425038-27-2
- Formula: C38H49N6NaO9S
- Molecular Weight:788.89
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Grazoprevir sodium salt
More- Signal Transduct Target Ther. 2021 May 29;6(1):212. [Abstract]
- Nature. 2026 Feb;650(8103):1035-1044. [Abstract]
- Cancer Cell. 2024 Nov 11;42(11):1955-1969.e7. [Abstract]
- Cancer Cell. 2022 Nov 14;40(11):1294-1305.e4. [Abstract]
- Nat Biotechnol. 2019 Oct;37(10):1209-1216. [Abstract]
- Nat Methods. 2018 Jul;15(7):519-522. [Abstract]
- Nat Commun. 2020 Sep 4;11(1):4417. [Abstract]
- Cancer Immunol Res. 2021 Sep;9(9):999-1007. [Abstract]
- Pharmaceuticals (Basel). 2022 Feb 18;15(2):242. [Abstract]
- J Gastroenterol. 2019 May;54(5):449-458. [Abstract]
- Sci Rep. 2022 Jul 16;12(1):12197. [Abstract]
- Sci Rep. 2019 Apr 5;9(1):5722. [Abstract]
- Antiviral Res. 2022 Jan:197:105224. [Abstract]
- Antiviral Res. 2019 Nov:171:104612. [Abstract]
- Antiviral Res. 2017 Mar:139:18-24. [Abstract]
- Development. 2025 Jun 1;152(11):dev204505. [Abstract]
- J Pharm Biomed Anal. 2020 Jan 30:178:112964. [Abstract]
- J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Mar 15:1110-1111:15-24. [Abstract]
- bioRxiv. 2024 Dec 3:2024.11.26.625483. [Abstract]
- Patent. US12065501.
- University of Glasgow. 2024 Mar.
- bioRxiv. 2024 Mar 12.
- Research Square Preprint. 2024 Jan 23.
- bioRxiv. 2023 Oct 26:2023.10.26.561921. [Abstract]
- bioRxiv. 2023 Feb 27:2023.02.27.530290. [Abstract]
- Patent. US20220025003A1.
- Elife. 2020 Jun 9:9:e56469. [Abstract]
- Patent. US20190010245A1.
- Patent. US20180346589A1.
Customer Validation & Images
-
ELISA
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
-
In Vivo Imaging
-
In Vivo Efficacy Study
Biological Activity
Chemical Information
-
CAS No. 1425038-27-2
-
Molecular Weight 788.89
-
Formula C38H49N6NaO9S
-
SMILES
COC1=CC2=C(N=C(CCCCC[C@@H]3C[C@H]3OC4=O)C(O[C@H]5CN(C([C@H](C(C)(C)C)N4)=O)[C@H](C(N[C@@]([C@@H]6C=C)(C6)C([N-]S(C7CC7)(=O)=O)=O)=O)C5)=N2)C=C1.[Na+]
-
Synonyms
MK-5172 sodium salt
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (29)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. [Abstract]2021 May 29;6(1):212. PMID: 34052830 -
Nature
2026 Feb;650(8103):1035-1044. PMID: 41535463 -
Cancer Cell
2024 Nov 11;42(11):1955-1969.e7. PMID: 39532065 -
Cancer Cell
2022 Nov 14;40(11):1294-1305.e4. PMID: 36084652
Grazoprevir sodium salt purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2022 Nov 14;40(11):1294-1305.e4. [Abstract]
Primary T cell lines were treated with or without Grazoprevir (all in the presence of target cells), and cytokine levels quantified.
Grazoprevir sodium salt purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2022 Nov 14;40(11):1294-1305.e4. [Abstract]
Cytotoxicity response of OFF VIPER CAR T cells to Grazoprevir being added, washed out, and re-introduced after two days.
Grazoprevir sodium salt purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2022 Nov 14;40(11):1294-1305.e4. [Abstract]
Grazoprevir dose-response profile of various cells, as measured in cytokine levels and cell killing.
Grazoprevir sodium salt purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2022 Nov 14;40(11):1294-1305.e4. [Abstract]
IVIS imaging of groups treated with (1) no T cells, (2) non-transduced T cell (NT-WT), (3) ON VIPER CAR T cells, (4) ON VIPER CAR T cells with Grazoprevir (5) OFF VIPER CAR T cells, (6) OFF VIPER CAR T cells with Grazoprevir, or (7) Traditional CAR T cells by day 21.
Grazoprevir sodium salt purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2022 Nov 14;40(11):1294-1305.e4. [Abstract]
Illustration of the dual-tumor model generated by systemically growing Nalm6 cells via i.v. and regional growth of MSTO-211H cells via s.c (left). Timeline for the in vivo experiment (right). Inducers (Grazoprevir or POM) were injected daily through i.p.
-
Nat Biotechnol
Multi-input chemical control of protein dimerization for programming graded cellular responses. [Abstract]2019 Oct;37(10):1209-1216. PMID: 31501561 -
Nat Methods
2018 Jul;15(7):519-522. PMID: 29967495 -
Nat Commun
Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. [Abstract]2020 Sep 4;11(1):4417. PMID: 32887884 -
Cancer Immunol Res
CRASH-IT Switch Enables Reversible and Dose-Dependent Control of TCR and CAR T-cell Function. [Abstract]2021 Sep;9(9):999-1007. PMID: 34193461 -
Pharmaceuticals (Basel)
Evaluation of the Potency of Anti-HIV and Anti-HCV Drugs to Inhibit P-Glycoprotein Mediated Efflux of Digoxin in Caco-2 Cell Line and Human Precision-Cut Intestinal Slices. [Abstract]2022 Feb 18;15(2):242. PMID: 35215354 -
J Gastroenterol
Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice. [Abstract]2019 May;54(5):449-458. PMID: 30684016 -
Sci Rep
Hepatitis C virus NS3/4A inhibitors and other drug-like compounds as covalent binders of SARS-CoV-2 main protease. [Abstract]2022 Jul 16;12(1):12197. PMID: 35842458 -
Sci Rep
Impact of novel NS5A resistance-associated substitutions of hepatitis C virus detected in treatment-experienced patients. [Abstract]2019 Apr 5;9(1):5722. PMID: 30952914 -
Antiviral Res
Identification of a novel replication-competent hepatitis C virus variant that confers the sofosbuvir resistance. [Abstract]2022 Jan:197:105224. PMID: 34864126 -
Antiviral Res
Construction and characterization of Genotype-3 hepatitis C virus replicon revealed critical genotype-3-specific polymorphism for drug resistance and viral fitness. [Abstract]2019 Nov:171:104612. PMID: 31542377 -
Antiviral Res
A profiling study of a newly developed HCVcc strain PR63cc's sensitivity to direct-acting antivirals. [Abstract]2017 Mar:139:18-24. PMID: 28025084 -
Development
Small molecule- and cell contact-inducible systems for controlling expression and differentiation in mouse embryonic stem cells. [Abstract]2025 Jun 1;152(11):dev204505. PMID: 40377146 -
J Pharm Biomed Anal
Simultaneous determination of elbasvir and grazoprevir in fixed-dose combination and mass spectral characterization of each degradation product by UHPLC-ESI-QTOF-MS/MS. [Abstract]2020 Jan 30:178:112964. PMID: 31711865 -
J Chromatogr B Analyt Technol Biomed Life Sci
Quantification of second generation direct-acting antivirals daclatasvir, elbasvir, grazoprevir, ledipasvir, simeprevir, sofosbuvir and velpatasvir in human plasma by UPLC-MS/MS. [Abstract]2019 Mar 15:1110-1111:15-24. PMID: 30776611 -
bioRxiv
High-resolution profiling reveals coupled transcriptional and translational regulation of transgenes. [Abstract]2024 Dec 3:2024.11.26.625483. PMID: 39651241 -
-
-
-
-
bioRxiv
2023 Oct 26:2023.10.26.561921. PMID: 37961502 -
bioRxiv
Controlled protein activities with viral proteases, antiviral peptides, and antiviral drugs. [Abstract]2023 Feb 27:2023.02.27.530290. PMID: 36909459 -
-
Elife
Acute disruption of the synaptic vesicle membrane protein synaptotagmin 1 using knockoff in mouse hippocampal neurons. [Abstract]2020 Jun 9:9:e56469. PMID: 32515733 -
-
Purity & Documentation
References
[2]. Summa V, Ludmerer SW, McCauley JA, MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother. 2012 Aug;56(8):4161-7. [Content Brief]
[3]. Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6(1):212. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Grazoprevir sodium salt Related Classifications
HY-15298C Related Classifications
Powered by Bioz